A Canadian team conducted a single-center study of 41 people with refractory myositis treated with tofacitinib after failure of four to five immunosuppressants:
- 23 had classical dermatomyositis, 12 an amyopathic form and 6 polymyositis;
- tofacitinib produced statistically and clinically significant skin improvement in the dermatomyositis group,
- but had no significant effect on muscle in all participants,
- At the end of the study, 19 patients remained on tofacitinib, nine of them as monotherapy,
- 22 patients had discontinued the JAK inhibitor due to death from another cause (24.4%), lack of efficacy (19.5%), side effects (7.3%) or high cost (2.4%).
